Source comparison
Tesamorelin + Ipamorelin Blend vs Single-Agent GH Protocols: Research Comparison
Tesamorelin 1mg daily alone +28–35% 1.8–2.4 kg Minimal $480–720 Effective GHRH analog but limited by single-pathway stimulation. IGF-1 response plateaus around week 8 Ipamorelin 300mcg daily alone +22–30% 1.2–1.8 kg None $360–540 Clean ghrelin mimetic with no
This comparison does not assign a generated winner or score.
- Tesamorelin 1mg daily alone
- +28–35%
- 1.8–2.4 kg
- Minimal
- $480–720
- Effective GHRH analog but limited by single-pathway stimulation. IGF-1 response plateaus around week 8
- Ipamorelin 300mcg daily alone
- +22–30%
- 1.2–1.8 kg
- None
- $360–540
- Clean ghrelin mimetic with no prolactin/cortisol spike, but GH pulse amplitude lower than GHRH analogs
- Tesamorelin 1mg + Ipamorelin 200mcg daily
- +45–58%
- 3.2–4.1 kg
- $720–1080
- Dual-pathway synergy produces sustained IGF-1 elevation and lean mass accretion superior to either compound alone
- MK-677 25mg daily (oral secretagogue)
- +40–50%
- 2.5–3.2 kg
- Moderate
- $240–360
- Oral convenience but continuous receptor activation causes ghrelin-mediated appetite increase and gradual desensitization
- Recombinant GH 2 IU daily
- +60–75%
- 3.5–4.8 kg
- Moderate-High
- $2400–3600
- Direct exogenous GH bypasses endogenous regulation entirely. Superior anabolic effect but cost and side-effect profile significantly higher
- The data reveals a clear pattern: single-agent secretagogues produce measurable but modest lean mass gains, while the tesamorelin + ipamorelin blend approaches the efficacy of low-dose recombinant GH at a fraction of the cost and with a substantially cleaner side-effect profile. The synergy isn't marketing. It's receptor-level pharmacology that published endocrine research has validated repeatedly.